Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: AUManufacturing
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million
  • Under the plan, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are priced at 65 cents
  • This price represents a 17.3 per cent discount to the five-day volume-weighted average price
  • LGP will use the money to speed-up sales and marketing efforts in both Australia and overseas as well as expand its manufacturing capacity
  • Shares in Little Green Pharma have dropped 8.75 per cent and are trading at 73 cents each

Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million.

This follows on from a recently announced placement to sophisticated, experienced and professional investors to raise $22 million.

All up, around 34 million shares were issued to participants at 65 cents.

Under the SPP, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are also priced at 65 cents.

This price represents a 17.3 per cent discount to the five-day volume-weighted average price.

The company’s Australian-based Directors, Angus Caithness and Neale Fong, intend to apply for the maximum $30,000 worth.

In the event of oversubscriptions, LGP has the right to scale-back applications.

LGP will use the money from both the placement and share purchase plan to speed-up sales and marketing efforts in both Australian and overseas markets, and expand its manufacturing and cultivation capacity.

The plan is set to close on March 3 and shares will be issued on March 11 and begin trading on the ASX on March 12.

Shares in Little Green Pharma have dropped 8.75 per cent and are trading at 73 cents each at 1:56 pm AEDT.

LGP by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…